Vogel V, Kramer H J, Bäcker A, Meyer-Lehnert H, Jelkmann W, Fandrey J
Renal Section, Medical Polyclinic and Institute of Physiology I, University of Bonn, Germany.
Am J Hypertens. 1997 Mar;10(3):289-96. doi: 10.1016/s0895-7061(96)00410-4.
A rise in blood pressure is the main side effect of erythropoietin (EPO) treatment in patients with renal anemia. The mechanisms, however, by which EPO may cause hypertension are still unclear. We therefore investigated the effects of EPO on endothelin (ET) synthesis and cytosolic free calcium concentration ([Ca2+]i) in vascular endothelial cells. Porcine endothelial cells were isolated from thoracic aorta, pulmonary artery, and vena cava. Studies were performed with cells of the first subculture. ET concentrations were measured radioimmunologically. Changes in [Ca2+]i were determined with the fluorescent probe fura-2. Cytotoxicity was assessed by sodium 3'-[1-(phenyl-amino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)ben zene sulfonic acid hydrate (XTT) assay. ET synthesis was similar in cells of different vascular origins and was time-dependent, reaching approximately 2 pmol ET/mg protein within 12 h of incubation. EPO (12 to 200 U/mL) stimulated ET release time- and dose-dependently by up to 83.2% (P < .01) within 12 h in the absence of fetal calf serum and heparin. EPO induced an immediate significant rise in [Ca2+]i from 58 +/- 12 nmol/L to 495 +/- 85 nmol/L (P < .01) with a subsequent slow return to 257 +/- 3 nmol/L. During 2 h of incubation, the Ca-ionophore A 23187 (10(-8) mol/L) moderately but significantly stimulated endothelial ET synthesis. However, the Ca-channel blocker verapamil, the intracellular Ca-release blocker TMB-8, and nickel, an unspecific calcium channel blocker, had no consistent effects on [Ca2+]i or ET synthesis. The protein kinase C inhibitor H-7 stimulated basal [Ca2+]i and cellular ET synthesis. The tyrosine kinase inhibitor genistein suppressed the EPO-induced rise in [Ca2+]i and cellular ET synthesis. From these data we conclude that EPO may stimulate ET synthesis in vascular endothelial cells by activation of an EPO-receptor and via intracellular signalling mechanisms that comprise tyrosine kinase activation and a rise in [Ca2+]i. Therefore, the systemic hypertensive effects of EPO may be due at least in part to local stimulation of vascular endothelial ET synthesis via calcium mobilization.
血压升高是肾性贫血患者接受促红细胞生成素(EPO)治疗的主要副作用。然而,EPO导致高血压的机制仍不清楚。因此,我们研究了EPO对血管内皮细胞中内皮素(ET)合成及胞浆游离钙浓度([Ca2+]i)的影响。从猪的胸主动脉、肺动脉和腔静脉分离出内皮细胞。实验使用第一代传代培养的细胞进行。采用放射免疫法测定ET浓度。用荧光探针fura-2测定[Ca2+]i的变化。通过3'-[1-(苯基-氨基甲酰基)-3,4-四氮唑]-双(4-甲氧基-6-硝基)苯磺酸水合物(XTT)法评估细胞毒性。不同血管来源的细胞中ET合成情况相似,且呈时间依赖性,孵育12小时内达到约2 pmol ET/mg蛋白。在无胎牛血清和肝素的情况下,EPO(12至200 U/mL)在12小时内呈时间和剂量依赖性地刺激ET释放,最高可达83.2%(P <.01)。EPO使[Ca2+]i立即从58±12 nmol/L显著升高至495±85 nmol/L(P <.01),随后缓慢降至257±3 nmol/L。在孵育2小时期间,钙离子载体A 23187(10(-8) mol/L)适度但显著地刺激内皮细胞ET合成。然而,钙通道阻滞剂维拉帕米、细胞内钙释放阻滞剂TMB-8以及非特异性钙通道阻滞剂镍对[Ca2+]i或ET合成没有一致的影响。蛋白激酶C抑制剂H-7刺激基础[Ca2+]i和细胞ET合成。酪氨酸激酶抑制剂染料木黄酮抑制EPO诱导的[Ca2+]i升高和细胞ET合成。从这些数据我们得出结论,EPO可能通过激活EPO受体并经由包括酪氨酸激酶激活和[Ca2+]i升高的细胞内信号传导机制来刺激血管内皮细胞中的ET合成。因此,EPO的全身性高血压作用可能至少部分归因于通过钙动员对血管内皮ET合成的局部刺激。